Cancer Trends and the Importance of Prevention

Document Type : Mini Review

Author

Health Management Research Center and Department of Community Medicine, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran

10.29252/ijmr-040403

Abstract

Cancer is one of the leading causes of death worldwide. The incidence and mortality of cancer is expected to grow rapidly. In Iran cancer morbidity and mortality are gradually changing as a result of economic, demographic and epidemiological transition. Common cancers, such as breast, prostate, colorectal and stomach have different rates of morbidity and mortality in advanced countries and also in Iran. This differentiation has been attributed to prevention measures and activities to control cancer. Cancer prevention and control is one of the most important scientific and public health challenges of this era. A comprehensive cancer control program suggests various ways to control cancer and implements those that are the most cost-effective and beneficial for the largest part of the Iranian population. Thus, it is suggested that a cancer prevention program in three levels of prevention is conducted. The goal of primary prevention is controlling of cancer causes which will be done by preventing human exposure to the risk factors of cancer. Secondary prevention includes early detection of cancer based on the screening program and an effective and timely treatment. Tertiary prevention includes Palliative care to improve the quality of life of patients and their families facing these problems. Considering the existing facilities and the breadth of the primary health care network and human resources and scientific support, a comprehensive cancer control program must be integrated into the primary healthcare network in Iran.

Keywords

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. doi: 10.3322/caac.21442. pmid: 29313949.
  2. Stewart BWKP, Wild CP. World cancer report 2014. World Health Organization, 2017.
  3. Anand P, Kunnumakkara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res. 2008;25(9):2097-116. doi: 10.1007/s11095-008-9661-9. pmid: 18626751.
  4. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. doi: 10.1002/ijc.29210. pmid: 25220842.
  5. Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20(3):556-63. doi: 10.1093/annonc/mdn642. pmid: 19073863.
  6. Kolahdoozan S, Sadjadi A, Radmard AR, Khademi H. Five common cancers in Iran. Arch Iran Med. 2010;13(2):143-6. pmid: 20187669.
  7. Daroudi R, Akbari Sari A, Nahvijou A, Kalaghchi B, Najafi M, Zendehdel K. The Economic Burden of Breast Cancer in Iran. Iran J Public Health. 2015;44(9):1225-33. pmid: 26587497.
  8. Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, et al. Breast cancer in Iran: an epidemiological review. Breast J. 2007;13(4):383-91. doi: 10.1111/j.1524-4741.2007.00446.x. pmid: 17593043.
  9. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893-907. doi: 10.1158/1055-9965.EPI-10-0437. pmid: 20647400.
  10. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300. doi: 10.3322/caac.20073. pmid: 20610543.
  11. Heitz AE, Baumgartner RN, Baumgartner KB, Boone SD. Healthy lifestyle impact on breast cancer-specific and all-cause mortality. Breast Cancer Res Treat. 2018;167(1):171-81. doi: 10.1007/s10549-017-4467-2. pmid: 28861753.
  12. Moy L, Slanetz PJ, Moore R, Satija S, Yeh ED, McCarthy KA, et al. Specificity of mammography and US in the evaluation of a palpable abnormality: retrospective review. Radiology. 2002;225(1):176-81. doi: 10.1148/radiol.2251010999. pmid: 12355002.
  13. Welch HG, Prorok PC, O'Malley AJ, Kramer BS. Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. N Engl J Med. 2016;375(15):1438-47. doi: 10.1056/NEJMoa1600249. pmid: 27732805.
  14. Yazdizadeh B, Jarrahi AM, Mortazavi H, Mohagheghi MA, Tahmasebi S, Nahvijo A. Time trends in the occurrence of major GI cancers in Iran. Asian Pac J Cancer Prev. 2005;6(2):130-4. pmid: 16101320.
  15. Malekzadeh R, Derakhshan MH, Malekzadeh Z. Gastric cancer in Iran: epidemiology and risk factors. Arch Iran Med. 2009;12(6):576-83. pmid: 19877751.
  16. Riboli E, Norat T. Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. Am J Clin Nutr. 2003;78(3 Suppl):559S-69S. doi: 10.1093/ajcn/78.3.559S. pmid: 12936950.
  17. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106-30. pmid: 16514137.
  18. Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology. 2000;56(2):255-60. pmid: 10925089.
  19. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96. doi: 10.3322/CA.2007.0010. pmid: 18287387.
  20. Dolatkhah R, Somi MH, Bonyadi MJ, Asvadi Kermani I, Farassati F, Dastgiri S. Colorectal cancer in iran: molecular epidemiology and screening strategies. J Cancer Epidemiol. 2015;2015:643020. doi: 10.1155/2015/643020. pmid: 25685149.
  21. Dolatkhah R, Somi MH, Kermani IA, Ghojazadeh M, Jafarabadi MA, Farassati F, et al. Increased colorectal cancer incidence in Iran: a systematic review and meta-analysis. BMC Public Health. 2015;15:997. doi: 10.1186/s12889-015-2342-9. pmid: 26423906.
  22. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology. 2003;124(2):544-60. doi: 10.1053/gast.2003.50044. pmid: 12557158.
  23. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133-45. doi: 10.1002/ijc.27711. pmid: 22752881.
  24. Bonita R, De Courten M, Dwyer T, Jamrozik K, Winkelmann R. Surveillance of risk factors for noncommunicable diseases: The WHO STEPwise approach: Summary. Noncommunicable Diseases and Mental Health, World Health Organization, 2001.
  25. Vineis P, Wild CP. Global cancer patterns: causes and prevention. Lancet. 2014;383(9916):549-57. doi: 10.1016/S0140-6736(13)62224-2. pmid: 24351322.
  26. Smith RA, Cokkinides V, von Eschenbach AC, Levin B, Cohen C, Runowicz CD, et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin. 2002;52(1):8-22. pmid: 11814067.
  27. Greenwald P. A favorable view: progress in cancer prevention and screening. Recent Results Cancer Res. 2007;174:3-17. pmid: 17302181.
  28. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev. 1993;15(1):36-47. pmid: 8405211.
  29. Colditz GA, Cannuscio CC, Frazier AL. Physical activity and reduced risk of colon cancer: implications for prevention. Cancer Causes Control. 1997;8(4):649-67. pmid: 9242482.
  30. Moyer VA, Force USPST. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-34. doi: 10.7326/0003-4819-157-2-201207170-00459. pmid: 22801674.
  31. MacDonald N. Palliative care--the fourth phase of cancer prevention. Cancer Detect Prev. 1991;15(3):253-5. pmid: 1711926.
International Journal of Medical Reviews
Volume 4, Issue 4
Autumn 2017
Pages 98-101

Files

History

  • Receive Date: 05 October 2017
  • Revise Date: 20 December 2017
  • Accept Date: 27 November 2017

Share

How to cite

Statistics